A new approach to Parkinson’s disease

Regenerative medicine company International Stem Cell Corporation (ISCO) leads the way in developing new treatments for Parkinson’s disease and other clinical conditions using a unique stem cell approach. To download the full article, please sign in.

Page of
Go to the profile of International Stem Cell Corporation

International Stem Cell Corporation

California-based ISCO is a clinical-stage biotechnology company developing novel stem cell–based therapies, with revenues of over $7 million in 2014 from its two subsidiary businesses: Lifeline Cell Technology, a leading manufacturer of purified primary human cells and optimized reagents for cell culture, and Lifeline Skin Care, which develops, manufactures and markets dermatological products containing stem cell extracts. The company’s therapeutic pipeline includes programs in neurology, ophthalmology and metabolic liver diseases. ISCO’s proprietary stem cell platform is based on parthenogenesis and produces pluripotent stem cells from unfertilized human eggs, a method the company has patented in the United States, Japan and the European Union (EU). Importantly, in the EU, where embryonic stem cells (ESCs) are unpatentable, the company has successfully prosecuted its patents, thereby gaining a significant competitive advantage. Against the backdrop of a cell-therapy renaissance across multiple clinical areas, ISCO provides unique partnering opportunities from preclinical to later stages of development.

Comments are disabled